PKC regulates αKlotho gene expression in MDCK and NRK-52E cells

Lisa Wolf, Julia E. Vogt, Jana Alber, Domenic Franjic, Martina Feger, Michael FöllerPflügers 2023 · DOI

TL;DR

Researchers have identified Protein Kinase C (PKC)—specifically the PKC$\gamma$ isoform—as a potent negative regulator of the anti-aging gene $\alpha$Klotho in kidney cells. By demonstrating that PKC activation suppresses $\alpha$Klotho while its inhibition boosts it, the study provides a molecular link between high-stress cellular signaling and the loss of Klotho’s protective, life-extending effects.

What Problem Does This Paper Address?

$\alpha$Klotho is often referred to as an "anti-aging" protein. Primarily expressed in the kidney, it acts as a co-receptor for FGF23 to regulate phosphate levels and circulates as a hormone that protects against inflammation, oxidative stress, and fibrosis. High levels of Klotho are associated with longevity and better outcomes in cardiovascular and renal diseases, while Klotho deficiency accelerates aging.

Conversely, Protein Kinase C (PKC) is a family of enzymes involved in various disease states, including cancer and diabetic nephropathy. While we know that high PKC activity and low Klotho levels often coincide in diseased tissues, the direct regulatory relationship between them remained unclear. This paper investigates whether PKC activity directly controls the expression of the $\alpha$Klotho gene.

Methods

The authors utilized two established renal cell models: MDCK (Madin-Darby canine kidney) and NRK-52E (normal rat kidney) cells. To dissect the signaling pathway, they employed a combination of pharmacological and molecular tools:

  • Activation: They used PMA (phorbol-12-myristate-13-acetate), a potent chemical activator of PKC.
  • Inhibition: They used broad-spectrum inhibitors like staurosporine and more selective inhibitors like Gö6976 and sotrastaurine to block specific PKC isoforms.
  • Genetic Silencing: To pinpoint the exact enzyme responsible, they used siRNA (small interfering RNA) to "knock down" specific PKC isoforms (PKC$\gamma$ and PKC$\eta$).
  • Measurement: Gene expression was quantified using qRT-PCR, and protein abundance was verified via Western Blotting.

Datasets

As a laboratory-based molecular biology study, this paper does not use large-scale public datasets or machine learning benchmarks. The "datasets" consist of primary experimental results generated from the MDCK and NRK-52E cell lines, including mRNA expression levels and protein quantification across multiple independent biological replicates ($n$ values ranging from 3 to 11).

Key Insights and Ideas

  • PKC as a "Brake": The most significant insight is that PKC acts as a negative regulator. When you turn PKC "on" (via PMA), $\alpha$Klotho expression drops. When you turn PKC "off" (via inhibitors), $\alpha$Klotho expression increases.
  • The PKC$\gamma$ Surprise: The study identified PKC$\gamma$ as the primary isoform responsible for this regulation. This was unexpected because PKC$\gamma$ is traditionally thought to be expressed almost exclusively in the brain/neurons. Finding it active and regulatory in renal cell lines suggests a broader role for this isoform than previously recognized.
  • Translational Potential: Because PKC inhibition (via staurosporine) significantly increased Klotho levels, the study suggests that targeting PKC could be a viable therapeutic strategy to restore Klotho levels in patients with kidney or heart disease.
  • Independence from Toxicity: While staurosporine can be toxic to cells, the authors showed that the increase in Klotho occurred even at very low concentrations, suggesting the effect is a specific signaling response rather than just a reaction to cellular stress.

Key Results

  • Dose-Dependent Suppression: In MDCK cells, PMA (30–300 nM) significantly reduced $\alpha$Klotho mRNA. In NRK-52E cells, concentrations $\ge$ 100 nM had the same effect.
  • Boosting Klotho: Treating cells with 1 nM staurosporine (a PKC inhibitor) significantly enhanced $\alpha$Klotho mRNA abundance in both cell lines.
  • Protein Confirmation: In NRK-52E cells, Western Blotting confirmed that PKC inhibition led to a measurable increase in actual $\alpha$Klotho protein, not just mRNA.
  • Isoform Specificity: Silencing PKC$\gamma$ with siRNA increased baseline $\alpha$Klotho expression and partially blunted the suppressive effects of PMA. In contrast, silencing PKC$\eta$ had no effect on Klotho levels, narrowing the search to the $\gamma$ isoform.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted entirely in immortalized cell lines. The authors acknowledge that while PKC$\gamma$ is dominant in these specific cells, it is expressed at very low levels in adult kidneys. They suggest that a different PKC isoform might take over this regulatory role in a living organism.
  • The "How" is Missing: The paper establishes that PKC regulates Klotho, but it doesn't identify the downstream transcription factors or exact molecular "messengers" that travel from the PKC enzyme to the Klotho gene promoter.
  • Clinical Safety: Broad PKC inhibitors like staurosporine are too toxic for human use. Future research will need to identify more specific, less toxic ways to target the PKC-Klotho axis to be clinically useful.

Summary updated

Abstract

Particularly expressed in the kidney, αKlotho is a transmembrane protein that acts together with bone hormone fibroblast growth factor 23 (FGF23) to regulate renal phosphate and vitamin D homeostasis. Soluble Klotho (sKL) is released from the transmembrane form and controls various cellular functions as a paracrine and endocrine factor. αKlotho deficiency accelerates aging, whereas its overexpression favors longevity. Higher αKlotho abundance confers a better prognosis in cardiovascular and renal disease owing to anti-inflammatory, antifibrotic, or antioxidant effects and tumor suppression. Serine/threonine protein kinase C (PKC) is ubiquitously expressed, affects several cellular responses, and is also implicated in heart or kidney disease as well as cancer. We explored whether PKC is a regulator of αKlotho. Experiments were performed in renal MDCK or NRK-52E cells and PKC isoform and αKlotho expression determined by qRT-PCR and Western Blotting. In both cell lines, PKC activation with phorbol ester phorbol-12-myristate-13-acetate (PMA) downregulated, while PKC inhibitor staurosporine enhanced αKlotho mRNA abundance. Further experiments with PKC inhibitor Gö6976 and RNA interference suggested that PKCγ is the major isoform for the regulation of αKlotho gene expression in the two cell lines. In conclusion, PKC is a negative regulator of αKlotho gene expression, an effect which may be relevant for the unfavorable effect of PKC on heart or kidney disease and tumorigenesis.
BibTeX
@inproceedings{wolf2023pkc,
  author = {Lisa Wolf and Julia E. Vogt and Jana Alber and Domenic Franjic and Martina Feger and Michael Föller},
  title = {{PKC regulates αKlotho gene expression in MDCK and NRK-52E cells}},
  booktitle = {Pflügers},
  year = {2023},
  doi = {10.1007/s00424-023-02863-3},
}
Figure